Search

everythinglearnresearchcommunity

for

Search:↓

Oral PTD-DBM was discussed as a potential hair loss treatment, but it was deemed ineffective in humans despite promising results in mice. The conversation concluded that trying it without VPA might be unwise.

A 30-year-old man experienced significant hair loss after starting testosterone replacement therapy (TRT), which did not improve with daily finasteride and minoxidil. He is considering restarting TRT and is seeking advice on using pyrilutamide or RU58841 to prevent further hair loss.

User received Trichotest results not recommending Finasteride. They are on Oral Minoxidil 2.50 and considering adding Finasteride.

PP405 shows significantly better early-stage hair regrowth results compared to minoxidil and finasteride, with 31% of users experiencing over 20% density increase in 4–8 weeks. Minoxidil and finasteride show minimal or no visible regrowth in the same timeframe.

Tae147 has shared results of using pyrilutamide, a 5% concentration topical solution applied twice daily, in combination with minoxidil, to reduce scalp itchiness and hair shedding. Other users have shared their experiences with the treatment, as well as questions about its availability on the market.

The conversation discusses maintaining hair regrowth using minoxidil and finasteride and whether using gt20029, which degrades androgen receptors, would affect this. Fluridil, a similar treatment, can disable over 90% of active androgen receptors.

Using 0.025% tretinoin may enhance minoxidil's effects for hair loss. Users suggest starting with 0.025% and gradually increasing the concentration, and discuss combining treatments like microneedling.

Minoxidil sulfate is more effective than regular minoxidil, especially for those with low sulfotransferase levels or scalp sensitivity, but it is unstable unless delivered in a liposomal format. Combining minoxidil with tretinoin can enhance effectiveness, and stopping minoxidil use can lead to rapid hair loss.

A 43-year-old male with advanced hair loss is experimenting with alternative treatments, including red light therapy, microneedling, scalp massages, an oil mix, and ketoconazole shampoo, after previously experiencing side effects from finasteride and minoxidil. He noticed some minor changes with red light therapy but remains skeptical about significant improvement.

Pyrilutamide is a selective AR antagonist with a high binding affinity, making it effective in competing with DHT for androgen receptors. The 1% concentration is more effective than the 0.5%, but the latter may suffice for mild hair loss; the drug is considered a good option for those avoiding 5AR blockers due to side effects.

A trans man experiencing hair loss after starting testosterone treatment has seen positive results using topical minoxidil and finasteride, though his hair remains thin. He is considering continuing his current treatment and exploring additional options like microneedling and Breezula, while acknowledging the impact of testosterone on hair loss.

The conversation discusses how Tretinoin may improve the effectiveness of Minoxidil for treating hair loss by increasing the activity of certain enzymes in hair follicles. One user comments that this information is not new.

The potential of using a specific antibody, HMI-115, as a treatment for hair loss alongside traditional treatments such as minoxidil and finasteride. The user suggests trying either a 240 mg or 30 mg dose to see if it works.

GT20029 shows promising results for hair loss treatment, with potential approval in China by 2026 or 2027, but U.S. approval may take longer. It could serve as an alternative to finasteride, with a potentially better side effect profile.

A trans woman is using 10 mg oral minoxidil, dutasteride, and estradiol for hair regrowth and is also doing dermastamping despite the pain. Users discuss the benefits of dermastamping for serum absorption and hair follicle stimulation, with some expressing surprise at the high minoxidil dosage.

Kintor's Phase II U.S. trials for pyrilutamide and the process of pharmaceutical drugs coming to market, with a reply from someone who has just ordered 500mg of Pyrilutamide to start their own phase trials.

This user has conducted data scraping of 365 Reddit posts on the hairloss drug Pyrilutamide over the last year to analyse efficacy and side effects. The findings, which are available in a 19 page report with graphs, suggest that 22% of Pyrilutamide users experience positive results while 63% experience symptoms. A larger analytics project is proposed for other drugs with enough demand.

A user is concerned about low testosterone while using finasteride 0.625mg MWF and considers ashwagandha for stress. Others suggest exercise, magnesium, and not worrying about testosterone levels if no significant side effects are felt.

Hair loss treatments including Minoxidil, Finasteride and RU58841; with a focus on Pyrilutamide could potentially be used as an effective treatment.

Minoxidil and LLLT are compared for treating hair loss, with LLLT showing higher regrowth rates and fewer side effects. LLLT is less time-consuming and more suitable for those with health issues, while Minoxidil requires daily application.

The user has been using a topical treatment combining finasteride, minoxidil, and caffeine for 9 months without noticing any changes and is inquiring about blood tests to check for finasteride resistance. They had their DHT levels checked, which were 54 ng/dl, and are planning to share progress pictures soon.

Pyrilutamide, a nonsteroidal antiandrogen drug under development for the potential treatment of androgenic alopecia. The conversation discusses its binding affinity to the androgen receptor and the timeline for possible availability after trials are completed in the United States and China.

Pyrilutamide's effectiveness is questioned due to overstated claims and previous trial ineffectiveness, with some users opting for finasteride instead. Despite skepticism, some consider adding pyrilutamide to their regimen alongside treatments like bicalutamide.

The conversation is about the difficulty in obtaining GT20029, a hair loss treatment, due to patent issues and the need to resort to group buys or Chinese labs for acquisition. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.

The conversation discusses the lack of updates on GT20029 for hair loss treatment, with some users noting recent reports indicating ongoing data collection. There are mentions of other treatments like Pyrilutamide and Minoxidil.

The user did not respond to minoxidil and is considering using tretinoin to improve results. They also explored finasteride, microneedling, adapalene, red light therapy, and oral minoxidil as potential treatments.

Amplifica is testing a compound called AMP-303 for hair loss, but it's not Scube3 or osteopontin. The timing for the results from the clinical trial is unknown.

New hair loss treatments like GT20029 and PP405 could potentially replace minoxidil and finasteride, offering better results with fewer side effects. However, current treatments like finasteride and minoxidil are still effective for many, despite concerns about side effects.

The conversation is about the delay in the release of GT20029 phase 2 results by Kintor. It also mentions Minoxidil, finasteride, and RU58841 as treatments for hair loss.

User asks if HMI 115 hasn't done phase 1 for AGA in humans. Conversation includes treatments Min, Fin, and RU.